Advanced in Thrombocytopenia

Rob Ter Heine

Radboud UMC
Nijmegen, GE, NL 
Advanced in Thrombocytopenia
Radboud UMC
Nijmegen, GE, NL 
OverviewLocationsClinical Research

Overview

Rob Ter Heine practices in Nijmegen, Netherlands. Mr. Ter Heine is rated as an Advanced expert by MediFind in the treatment of Thrombocytopenia. His top areas of expertise are Atypical Hemolytic Uremic Syndrome (aHUS), D-Minus Hemolytic Uremic Syndrome, D-Plus Hemolytic Uremic Syndrome, Hemolytic-Uremic Syndrome, and Kidney Transplant.

His clinical research consists of co-authoring 176 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 8 articles in the study of Thrombocytopenia.

Gender
Male

Locations

Radboud UMC
Nijmegen, GE 6525GA, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response
Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response
Enrollment Status: Completed
Publish Date: December 17, 2024
Intervention Type: Drug
Study Drug: Pemetrexed
Study Phase: Phase 4
Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response
Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response
Enrollment Status: Terminated
Publish Date: May 13, 2022
Intervention Type: Drug
Study Drug: Pemetrexed
Study Phase: Phase 4
Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response
Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response
Enrollment Status: Completed
Publish Date: May 10, 2022
Intervention Type: Drug
Study Drug: Pemetrexed
Study Phase: Phase 4
View 2 Less Clinical Trials

176 Total Publications

TDM-Based Tailored Dosing of Durvalumab in Lung Cancer Patients: A Comprehensive Population Pharmacokinetic-Pharmacoeconomic Evaluation.
TDM-Based Tailored Dosing of Durvalumab in Lung Cancer Patients: A Comprehensive Population Pharmacokinetic-Pharmacoeconomic Evaluation.
Journal: Clinical pharmacokinetics
Published: July 14, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Ter Heine's expertise for a condition
ConditionClose
    View All 13 Advanced Conditions
    View All 21 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile